Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ovid Therapeutics (OVID) Net Margin (2020 - 2025)

Historic Net Margin for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to 9210.61%.

  • Ovid Therapeutics' Net Margin fell 11146500.0% to 9210.61% in Q3 2025 from the same period last year, while for Sep 2025 it was 556.01%, marking a year-over-year decrease of 5414600.0%. This contributed to the annual value of 4670.14% for FY2024, which is 86816400.0% up from last year.
  • As of Q3 2025, Ovid Therapeutics' Net Margin stood at 9210.61%, which was down 11146500.0% from 74.68% recorded in Q2 2025.
  • Over the past 5 years, Ovid Therapeutics' Net Margin peaked at 5042.01% during Q2 2024, and registered a low of 107798.33% during Q3 2022.
  • In the last 5 years, Ovid Therapeutics' Net Margin had a median value of 7873.08% in 2025 and averaged 12316.36%.
  • Data for Ovid Therapeutics' Net Margin shows a peak YoY increase of 974744800bps (in 2023) and a maximum YoY decrease of -184465800bps (in 2023) over the last 5 years.
  • Over the past 5 years, Ovid Therapeutics' Net Margin (Quarter) stood at 11.76% in 2021, then soared by 56bps to 5.17% in 2022, then plummeted by -33bps to 6.88% in 2023, then tumbled by -117625bps to 8095.95% in 2024, then dropped by -14bps to 9210.61% in 2025.
  • Its last three reported values are 9210.61% in Q3 2025, 74.68% for Q2 2025, and 7873.08% during Q1 2025.